Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

[1]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[2]  A. Bergman,et al.  Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment , 2014, Cancer.

[3]  O. Sartor,et al.  Castration-resistant prostate cancer: adaptive responses in the androgen axis. , 2014, Cancer treatment reviews.

[4]  M. Cronauer,et al.  Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. , 2014, European urology.

[5]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[6]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[7]  A. Armstrong,et al.  Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Bono,et al.  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  T. D. de Reijke,et al.  Prostate cancer: ESMO Consensus Conference Guidelines 2012. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[11]  S. Culine,et al.  ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[13]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[14]  A. Joshua,et al.  Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. , 2012, Current oncology.

[15]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[16]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[17]  R. DiPaola,et al.  Abiraterone in Prostate Cancer: A New Angle to an Old Problem , 2012, Clinical Cancer Research.

[18]  H. Scher,et al.  ARN-509: a novel antiandrogen for prostate cancer treatment. , 2012, Cancer research.

[19]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[20]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[21]  K. Fizazi,et al.  Targeting Continued Androgen Receptor Signaling in Prostate Cancer , 2011, Clinical Cancer Research.

[22]  J. Arezzo,et al.  Drug safety is a barrier to the discovery and development of new androgen receptor antagonists , 2011, The Prostate.

[23]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[24]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[25]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[26]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[27]  S. Larson,et al.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[29]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Crawford,et al.  Adverse events associated with hormonal therapy for prostate cancer. , 2005, Reviews in urology.

[32]  T. McDonnell,et al.  The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.